<DOC>
	<DOCNO>NCT00512876</DOCNO>
	<brief_summary>Purpose : To determine efficacy safety one commonly use VEGF inhibitor , bevacizumab ( Avastin , Genentech ) , topical agent treatment corneal neovascularization .</brief_summary>
	<brief_title>Effectiveness Safety Topical Bevacizumab ( Avastin ) Treatment Corneal Neovascularization</brief_title>
	<detailed_description />
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Corneal Neovascularization</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>male female , least 18 year age clinically stable corneal neovascularization superficial deep corneal neovascularization extend far 2mm limbus ability understand provide inform consent participate study willingness follow study instruction likely complete require visit . Clinical stability follow criterial exclude corneal neovascularization regard clinically stable : current recent ( &lt; 3 month ) episode corneal ocular surface infection ( bacterial , viral , fungal , acanthamoebal ) recent ( &lt; 3 month ) ocular surgery , include cataract surgery , and/or laser type study eye recent ( &lt; 6 month ) full thickness lamellar keratoplasty recent ( &lt; 6 month ) ocular surface reconstruction , limbal auto allograft stem cell transplantation , amniotic membrane transplantation current recent ( &lt; 3 month ) use contact lens plan use contact lens ( exclude bandage contact lens ) current recent ( &lt; 3 month ) persistent corneal epithelial defect ( leat 14 day duration ) measure 1mm2 current recent ( &lt; 1 month ) systemic corticosteroid therapy periocular corticosteroid injection study eye current recent ( &lt; 3 month ) intravitreal durg injection study eye . recent ( &lt; 1 month ) change dose frequency topical steroid and/or nonsteroidal antiinflammatory agent uncontrolled hypertension define systolic blood pressure &gt; 150 mmHg diastolic blood pressure &gt; 90 mmHg history thromboembolic event , include myocardial infarction cerebral vascular accident patient age 75 old history renal abnormality recent ( &lt; 3 month ) plan surgery history coagulation abnormality , include end stage liver disease current anticoagulation medication aspirin ( warfarin , heparin , enoxaparin similar anticoagulant agent ) female patient childbearing potential exclude . A female consider childbearing potential unless postmenopausal without menses 12 month without uterus and/or ovary . condition ( include language barrier ) preclude patient 's ability comply study requirement include completion study . condition precludes patient 's ability assist family member 's ability apply medication drop sustain five minute pressure lacrimal duct drop application . concurrent enrollment another clinical investigation medicinal product device study prohibit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>